AKKARAJU SRINIVAS 4

What Happened

• Akkaraju Srinivas, reported as a 10% owner of Kalaris Therapeutics (KLRS), purchased 479,847 shares in a privately negotiated transaction on December 18, 2025. The shares were acquired at $10.42 per share for a total reported value of $5,000,006. This was a purchase (code P), which is generally viewed as a more informative signal than routine sales.

Key Details

• Transaction date and price: 12/18/2025 — 479,847 shares @ $10.42 each.
• Total value: $5,000,006.
• Shares held after transaction: The filing notes aggregate holdings in footnote (2) and references an amended prior Form 4 (Dec 22, 2025). The Form 4 does not list a single consolidated total in the main table; see footnotes for details on related fund holdings.
• Notable footnotes:
  • F1: Shares were purchased from Samsara BioCapital, L.P. in a privately negotiated sale.
  • F3–F5: Several related entities (Samsara Opportunity Fund, Samsara LP, and related GPs) hold shares; Srinivas is a managing member/has voting and investment power over some fund-held shares but disclaims beneficial ownership except to the extent of his pecuniary interest.
  • F2: The filing amends a prior Form 4 (Dec 22, 2025) and incorporates those reported purchases.
• Filing timeliness: The Form 4 was filed on 2026-02-17 for a 2025-12-18 transaction; the filing is marked late (L).

Context

• This was a private purchase between related investment entities (Samsara-affiliated funds), not an open-market buy. For insiders and 10% owners, holdings can reflect institutional arrangements and fund-level ownership; footnotes indicate transfers among affiliated funds and disclaimers of beneficial ownership except for pecuniary interest. Purchases like this can be more meaningful than routine sales, but the transaction’s private, fund-related nature and the ownership disclaimers are important for interpreting how much of the purchase reflects Srinivas’s direct economic interest.